G1 Therapeutics, Inc.

NasdaqGS:GTHX Stok Raporu

Piyasa değeri: US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

G1 Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

G1 Therapeutics has a total shareholder equity of $24.6M and total debt of $44.3M, which brings its debt-to-equity ratio to 180.2%. Its total assets and total liabilities are $98.7M and $74.1M respectively.

Anahtar bilgiler

180.2%

Borç/özkaynak oranı

US$44.32m

Borç

Faiz karşılama oranın/a
NakitUS$60.73m
EşitlikUS$24.59m
Toplam yükümlülüklerUS$74.10m
Toplam varlıklarUS$98.69m

Son finansal sağlık güncellemeleri

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GTHX's short term assets ($92.9M) exceed its short term liabilities ($37.5M).

Uzun Vadeli Yükümlülükler: GTHX's short term assets ($92.9M) exceed its long term liabilities ($36.6M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GTHX has more cash than its total debt.

Borcun Azaltılması: GTHX's debt to equity ratio has increased from 0% to 180.2% over the past 5 years.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GTHX has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if GTHX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Sağlıklı şirketleri keşfedin